Suven Life Sciences Limited — Board Meeting, 13-05-2025: Outcome of Board Meeting

Suven Life Sciences has announced a board meeting on the financial results for the quarter and half-year, reporting a consolidated net loss of ₹160.74 Cr for FY25, up from ₹105.08 Cr last year. R&D spending jumped to ₹1439.62 Cr, driven by advanced trials for CNS drug candidates like Masupirdine and Samelisant. The company plans to raise up to ₹857.64 Cr through fully convertible warrants to fuel R&D, clinical trials, and a new facility. Sudharani Jasti is set for re-appointment as Whole-time Director for five years. An EGM will be held to approve the fundraise.